ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia
September 06, 2018 08:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 06, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Two Upcoming Investor Conferences
August 29, 2018 17:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Aug. 29, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
August 22, 2018 17:00 ET
|
ContraFect Corporation
YONKERS, New York, Aug. 22, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Announces Second Quarter 2018 Financial Results
August 09, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Corporation Prices $10 Million Public Offering of Common Stock
July 27, 2018 09:00 ET
|
ContraFect Corporation
YONKERS, N.Y., July 27, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Corporation Announces Proposed Public Offering of Common Stock
July 26, 2018 16:12 ET
|
ContraFect Corporation
YONKERS, N.Y., July 26, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present at JMP Securities Life Sciences Conference
June 14, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., June 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present New Data on CF-301 (exebacase) and Lysins Targeting Gram-Negative Pathogens at ASM Microbe 2018
May 30, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., May 30, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Announces First Quarter 2018 Financial Results
May 10, 2018 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y. , May 10, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 11, 2018 09:00 ET
|
ContraFect Corporation
YONKERS, N.Y., April 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...